Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

A nostalgic hit built out of vintage pop-culture references captured the “If you liked that, you’ll like this” spirit of Netflix. In the summer of 2016, streaming TV was still figuring itself out.

An artist’s impression of a quantum electrodynamics simulation using 100 qubits of an IBM quantum computer. The spheres and lines denote the qubits and connectivity of the IBM quantum processor; gold ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Donald Trump reacts to alleged Russia hack into federal court system Scott Galloway has bold words for Americans on Social Security United States Issued 'Level 3' Travel Warning This Week Sharon Stone ...

The k-generalized Fibonacci numbers are defined as in [1]. A polyphase merge (merging an equal number of sequences from k tapes onto a single unused tape) using k+1 tapes is defined in terms of linear ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...